Literature DB >> 26212079

Functional Correction of Large Factor VIII Gene Chromosomal Inversions in Hemophilia A Patient-Derived iPSCs Using CRISPR-Cas9.

Chul-Yong Park1, Duk Hyoung Kim2, Jeong Sang Son3, Jin Jea Sung1, Jaehun Lee3, Sangsu Bae4, Jong-Hoon Kim3, Dong-Wook Kim5, Jin-Soo Kim6.   

Abstract

Hemophilia A is an X-linked genetic disorder caused by mutations in the F8 gene, which encodes the blood coagulation factor VIII. Almost half of all severe hemophilia A cases result from two gross (140-kbp or 600-kbp) chromosomal inversions that involve introns 1 and 22 of the F8 gene, respectively. We derived induced pluripotent stem cells (iPSCs) from patients with these inversion genotypes and used CRISPR-Cas9 nucleases to revert these chromosomal segments back to the WT situation. We isolated inversion-corrected iPSCs with frequencies of up to 6.7% without detectable off-target mutations based on whole-genome sequencing or targeted deep sequencing. Endothelial cells differentiated from corrected iPSCs expressed the F8 gene and functionally rescued factor VIII deficiency in an otherwise lethal mouse model of hemophilia. Our results therefore provide a proof of principle for functional correction of large chromosomal rearrangements in patient-derived iPSCs and suggest potential therapeutic applications.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26212079     DOI: 10.1016/j.stem.2015.07.001

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN: 1875-9777            Impact factor:   24.633


  103 in total

Review 1.  Creating and evaluating accurate CRISPR-Cas9 scalpels for genomic surgery.

Authors:  Mehmet Fatih Bolukbasi; Ankit Gupta; Scot A Wolfe
Journal:  Nat Methods       Date:  2016-01       Impact factor: 28.547

Review 2.  Current Progress in Therapeutic Gene Editing for Monogenic Diseases.

Authors:  Versha Prakash; Marc Moore; Rafael J Yáñez-Muñoz
Journal:  Mol Ther       Date:  2016-01-14       Impact factor: 11.454

3.  Endothelial cells derived from patients' induced pluripotent stem cells for sustained factor VIII delivery and the treatment of hemophilia A.

Authors:  Melanie Rose; Kewa Gao; Elizabeth Cortez-Toledo; Emmanuel Agu; Alicia A Hyllen; Kelsey Conroy; Guangjin Pan; Jan A Nolta; Aijun Wang; Ping Zhou
Journal:  Stem Cells Transl Med       Date:  2020-03-12       Impact factor: 6.940

Review 4.  A CRISPR Path to Engineering New Genetic Mouse Models for Cardiovascular Research.

Authors:  Joseph M Miano; Qiuyu Martin Zhu; Charles J Lowenstein
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-04-21       Impact factor: 8.311

Review 5.  CRISP Points on Establishing CRISPR-Cas9 In Vitro Culture Experiments in a Resource Constraint Haematology Oncology Research Lab.

Authors:  Jhumki Das; Prateek Bhatia; Aditya Singh
Journal:  Indian J Hematol Blood Transfus       Date:  2018-09-17       Impact factor: 0.900

Review 6.  Enhancing the Therapeutic Potential of Mesenchymal Stem Cells with the CRISPR-Cas System.

Authors:  Daniel Mendes Filho; Patrícia de Carvalho Ribeiro; Lucas Felipe Oliveira; Ana Luiza Romero Terra Dos Santos; Ricardo Cambraia Parreira; Mauro Cunha Xavier Pinto; Rodrigo Ribeiro Resende
Journal:  Stem Cell Rev Rep       Date:  2019-08       Impact factor: 5.739

Review 7.  A genome editing primer for the hematologist.

Authors:  Megan D Hoban; Daniel E Bauer
Journal:  Blood       Date:  2016-04-06       Impact factor: 22.113

Review 8.  Customizing the genome as therapy for the β-hemoglobinopathies.

Authors:  Matthew C Canver; Stuart H Orkin
Journal:  Blood       Date:  2016-04-06       Impact factor: 22.113

Review 9.  Genome editing comes of age.

Authors:  Jin-Soo Kim
Journal:  Nat Protoc       Date:  2016-08-04       Impact factor: 13.491

Review 10.  Somatic Engineering of Oncogenic Chromosomal Rearrangements: A Perspective.

Authors:  Danilo Maddalo; Andrea Ventura
Journal:  Cancer Res       Date:  2016-08-12       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.